Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. reports clinical, corporate, and financing developments as a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other cancers. Olema Oncology updates commonly center on palazestrant (OP-1250), an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, and OP-3136, an orally available KAT6 inhibitor.
Recurring company news covers clinical and preclinical presentations at oncology meetings, endocrine-driven cancer biology, ER+/HER2- breast cancer studies, combination approaches with endocrine therapy and CDK inhibitors, operating results, public offerings, inducement equity grants, and board or management changes.
Olema Oncology (Nasdaq: OLMA) reported first quarter 2026 financial and operating results and highlighted upcoming clinical milestones in metastatic breast cancer.
The company ended the quarter with $505.3 million in cash and securities, while net loss increased to $53.1 million on higher R&D and G&A expenses supporting late-stage trials.
Top-line data from the pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy are expected in fall 2026. Enrollment continues in the pivotal Phase 3 OPERA-02 trial of palazestrant plus ribociclib, and first clinical data from OP-3136 Phase 1 will be presented at ASCO 2026.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to five new employees to purchase an aggregate of 154,700 shares, effective May 1, 2026. The options vest over four years (25% after one year, then monthly over three years), have a 10-year term and an exercise price of $14.32 per share, equal to the last reported sale price on May 1, 2026. Awards were approved by the Compensation Committee and granted under the company’s 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA) appointed Prakash Raman, Ph.D., to its Board of Directors on April 29, 2026. Dr. Raman brings over two decades of biopharmaceutical leadership and business development experience, including roles at InduPro Therapeutics, Ribon Therapeutics, Flagship Pioneering, and Novartis.
Olema said the appointment comes as the company advances palazestrant through two Phase 3 trials and prepares for pivotal OPERA-01 data this fall, while also progressing OP-3136, a potential KAT6 inhibitor.
Olema Oncology (NASDAQ: OLMA) will present initial clinical data for OP-3136 from a Phase 1 first-in-human study and a trial-in-progress poster for the Phase 3 OPERA-02 trial at the ASCO Annual Meeting, May 29–June 2, 2026 in Chicago.
The OP-3136 poster (Abstract 3088, Poster 225) is scheduled for May 30, 2026, 1:30pm–4:30pm CT; the OPERA-02 poster (Abstract TPS1152, Poster 261b) is scheduled for June 1, 2026, 1:30pm–4:30pm CT.
Olema Oncology (Nasdaq: OLMA) announced preclinical AACR posters showing palazestrant fully recruits corepressor NCoR1 to achieve complete estrogen receptor antagonism and robust in vitro anti-tumor activity.
Data also show OP-3136, a KAT6 inhibitor, synergizes with palazestrant in ER+/HER2- models; palazestrant is in two Phase 3 trials and OP-3136 is enrolling in Phase 1. Posters presented April 20, 2026 at AACR.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to four new employees to purchase an aggregate of 188,500 shares, effective April 1, 2026, under the company's 2022 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
The options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $15.12, equal to the last reported Nasdaq sale price on April 1, 2026.
Olema Oncology (Nasdaq: OLMA) will present two preclinical posters at the AACR Annual Meeting in San Diego, April 17-22, 2026. Both presentations are scheduled on April 20, 2026 in the session "Experimental and Molecular Therapeutics: Cellular Responses to Anticancer Drugs."
Poster 2950 reports that palazestrant recruits corepressor NCoR1 leading to complete ERα antagonism; poster 2949 describes palazestrant plus OP-3136 synergistically downregulating proliferation and metastasis gene signatures.
Olema Oncology (Nasdaq: OLMA) reported Q4 and full-year 2025 results, highlighting late-stage progress for palazestrant and early data plans for OP-3136. The company raised approximately $218.5 million in a follow-on offering and ended 2025 with $505.4 million in cash, cash equivalents, and marketable securities.
Operationally, OPERA-01 top-line data are expected in fall 2026, OPERA-02 enrollment is advanced, a Phase 1b/2 study with Pfizer began, and OP-3136 initial clinical data are anticipated in Q2 2026.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to four new employees to purchase an aggregate of 205,000 shares, effective March 2, 2026.
The options vest over four years (25% after one year, then monthly over three years), have a 10-year term and an exercise price of $24.02, equal to the last reported Nasdaq sale price on March 2, 2026.
Olema Oncology (Nasdaq: OLMA) announced that CEO Sean P. Bohen, M.D., Ph.D. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 2:30 p.m. ET. A live webcast and recording will be available on Olema’s investor relations site, subject to event host permissions.